MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: *Investment Round
Venture Capital: Series A
Resolve Therapeutics
Parents
*Architects: Biotechnology_Immunotherapy & Inflammation
*Architects: Lupus
Venture Capital: Series A
Children
Biotechnology company that is dedicated to helping patients with lupus through the development of RSLV-125, its novel targeted biologic therapy.
Raised $2 million in the initial close of a Series A financing from New York-based venture firms New Science Ventures, and Easton Capital.(2011)
Resolve Therapeutics Nabs $2M For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A 5/17/2011
RSLV-125 represents a new approach to inhibiting the production of interferon-alpha at a proximal step in the inflammatory cascade.
Seattle, Washington